https://www.selleckchem.com/pr....oducts/Decitabine.ht
INTRODUCTION Multidrug resistance among bacteria increases the need for new therapeutic options. Tigecycline is one candidate drug, due to property of a wider anti-bacterial spectrum to multi-drug resistant (MDR) pathogens. However, it has still not been approved for use in pediatric patients. METHODS In this study the effectiveness and safety of tigecycline in children was assessed retrospectively. RESULTS A total of 36 pediatric patients, received tigecycline therapy with a median of 13 days (2-32 days). Tigecycline was used as a c
Like
Comment
Share
